Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
MNKD - MannKind Corporation
Market Cap 1.21B P/E - EPS this Y 425.00% Ern Qtrly Grth -
Income -11.94M Forward P/E 30.60 EPS next Y 92.30% 50D Avg Chg 7.00%
Sales 198.96M PEG 0.90 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book N/A EPS next 5Y 35.60% 52W High Chg -20.00%
Recommedations 1.70 Quick Ratio 3.04 Shares Outstanding 270.76M 52W Low Chg 58.00%
Insider Own 1.53% ROA 1.72% Shares Float 265.99M Beta 1.32
Inst Own 50.18% ROE - Shares Shorted/Prior 30.76M/35.75M Price 4.59
Gross Margin 68.45% Profit Margin -6.00% Avg. Volume 2,709,170 Target Price 7.08
Oper. Margin 18.19% Earnings Date May 7 Volume 2,813,672 Change 2.23%
Healthcare | Biotechnology | United States
About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation News
04/03/24 MannKind Repays Certain Debt Obligations
04/01/24 MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
03/29/24 Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
03/26/24 MannKind Announces CFO Transition
03/25/24 Jim Cramer Says You Should Avoid These 11 Stocks
03/11/24 INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
03/05/24 MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
03/04/24 MannKind Corporation Announces Participation at Upcoming Conferences
03/03/24 Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts
02/29/24 MannKind Full Year 2023 Earnings: Beats Expectations
02/28/24 MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript
02/28/24 Q4 2023 MannKind Corp Earnings Call
02/28/24 MannKind (MNKD) Q4 2023 Earnings Call Transcript
02/27/24 Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings
02/27/24 MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates
02/27/24 MannKind Corp (MNKD) Reports Substantial Revenue Growth in 2023
02/27/24 MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
02/20/24 MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
02/15/24 MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
02/12/24 13 Best NASDAQ Penny Stocks To Invest In
MNKD Chatroom

User Image TltFlush Posted - 1 hour ago

$MNKD @jlonards Remind him of this:

User Image TltFlush Posted - 1 hour ago

$MNKD OT @jlonards @troutguy @WalterPayton @FakeLong Who is the real SLEEPY? Sleepy Joe or Sleepy Don?

User Image TltFlush Posted - 2 hours ago

$MNKD

User Image bbtb Posted - 2 hours ago

$MNKD ceo should be kicked out no good vermin afrezza sales going up but he is doing nothing

User Image TltFlush Posted - 4 hours ago

$MNKD Can anyone remind @JumboMike ?

User Image Longiesunderwater Posted - 5 hours ago

$MNKD same old same old.

User Image JumboMike Posted - 5 hours ago

$MNKD You do laugh when people say "we are holding up well based upon the current market!" I mean this stock has been worthless forever in one of the strongest bull markets ever especially since the end of Oct 2023 through March 2024. The posters on this board are mostly pumptard sheep and have very little critical thinking skills when it comes to stock valuations. Whose trading around their positions? You can't make this shit up.

User Image TltFlush Posted - 5 hours ago

$MNKD

User Image bbtb Posted - 5 hours ago

$MNKD ceo is thief

User Image TltFlush Posted - 6 hours ago

$MNKD #Afrezza

User Image TltFlush Posted - 6 hours ago

$MNKD

User Image wildpig Posted - 6 hours ago

$MNKD NOTHING BUT A LEGIT MONEY SCAM..... MORON MIKE & THE USELESS BOD will ride mnkd into retirement or BK- whichever comes first. PARASITES nothing more.

User Image whiskyqueen Posted - 6 hours ago

$MNKD We are literally on the cusp of greatness.

User Image Kool_Aid_Mann Posted - 6 hours ago

$MNKD Anyone that thinks this CEO deserves an extra $7M for last year, much less should even keep his job needs to get a psych exam!

User Image JustAnotherJuggler Posted - 7 hours ago

$MNKD Off Topic:

User Image bbtb Posted - 7 hours ago

$MNKD the ceo total garbage

User Image WalterPayton Posted - 8 hours ago

$MNKD up .19 in AH!

User Image 63fury Posted - 8 hours ago

$MNKD Any news or volume to go with this after hours 4.61% rise?

User Image WalterPayton Posted - 9 hours ago

$MNKD Biden wrong once again said that Lego bridge collapse was an accident an hour after the collapse! Now our FBI is looking at as a criminal event! 😂😂🤪🤡

User Image Preacherclint10 Posted - 10 hours ago

$MNKD

User Image Igotzthis Posted - 11 hours ago

$MNKD I wonder how many $4 calls are out there for this Friday.

User Image evetsoloccip Posted - 11 hours ago

$MNKD

User Image evetsoloccip Posted - 11 hours ago

$MNKD $4.10 - $4.21

User Image evetsoloccip Posted - 11 hours ago

$MNKD I will drink to that................

User Image FrostytheHittman Posted - 12 hours ago

$MNKD Holding up pretty well fingers crossed 🤞🏼. Many getting hammered

User Image Dogcatfish Posted - 12 hours ago

$MNKD Had to block bbtb. That's just me.

User Image bbtb Posted - 12 hours ago

$MNKD what an asswipe ceo over paid diluting

User Image WalterPayton Posted - 12 hours ago

$MNKD Break out to the other side! 🕺🏻

User Image evetsoloccip Posted - 13 hours ago

$MNKD $4.12 - $4.21

User Image Dogcatfish Posted - 14 hours ago

$MNKD

Analyst Ratings
Cantor Fitzgerald Overweight Mar 15, 24
Cantor Fitzgerald Overweight Feb 28, 24
HC Wainwright & Co. Buy Jan 4, 24
Wedbush Outperform Oct 10, 23
HC Wainwright & Co. Buy Aug 14, 23
Cantor Fitzgerald Overweight Aug 8, 23
HC Wainwright & Co. Buy May 11, 23
HC Wainwright & Co. Buy Feb 27, 23
SVB Leerink Outperform Nov 9, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Castagna Michael Chief Executive Offi.. Chief Executive Officer Dec 14 Sell 4 200,482 801,928 2,148,665 12/15/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Nov 01 Sell 4.25 10,000 42,500 2,349,147 11/02/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Oct 02 Sell 4.08 10,000 40,800 2,359,147 10/03/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 4.61 10,000 46,100 2,436,039 09/05/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 4.78 8,100 38,718 798,835 08/28/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Aug 01 Sell 4.5686 10,000 45,686 2,496,735 08/01/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jul 03 Sell 4.04 10,000 40,400 2,506,735 07/07/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jun 01 Sell 4.5302 10,000 45,302 2,516,735 06/02/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 25 Sell 4.55 150,000 682,500 2,526,735 05/26/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary May 22 Sell 4.68 95,576 447,296 735,263 05/24/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 22 Sell 4.69 150,000 703,500 2,331,735 05/24/23
Binder Steven B. Chief Financial Offi.. Chief Financial Officer May 22 Sell 4.68 47,810 223,751 838,324 05/24/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer May 05 Sell 4.00 10,000 40,000 2,020,128 05/05/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Apr 03 Sell 4.1287 10,000 41,287 2,030,128 04/05/23
Castagna Michael Chief Executive Offi.. Chief Executive Officer Mar 01 Sell 5.2748 10,000 52,748 2,040,128 03/03/23
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 3.67 7,000 25,690 726,035 08/29/22
Galindo Alejandro EVP Endocrine Busine.. EVP Endocrine Business Unit Aug 22 Sell 3.85 4,615 17,768 777,075 08/23/22
Binder Steven B. Chief Financial Offi.. Chief Financial Officer Jul 31 Buy 2.93 791 2,318 728,997 08/01/22
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jul 31 Buy 2.93 3,147 9,221 2,084,486 08/01/22
Tross Stuart A Chief People & Workp.. Chief People & Workpl Officer Jul 31 Buy 2.93 4,581 13,422 830,650 08/01/22
Galindo Alejandro EVP Endocrine Busine.. EVP Endocrine Business Unit Jul 31 Buy 2.93 5,000 14,650 781,690 08/01/22
HOOPER ANTHONY C Director Director Feb 28 Buy 2.71 40,000 108,400 338,394 03/01/22
MUNDKUR CHRISTINE Director Director Feb 28 Buy 2.71 27,675 74,999 254,493 03/01/22
Galindo Alejandro Chief Commercial Off.. Chief Commercial Officer Jan 31 Buy 3.17 1,804 5,719 539,790 02/09/22
Castagna Michael Chief Executive Offi.. Chief Executive Officer Jan 31 Buy 3.17 1,804 5,719 1,505,098 02/09/22
Tross Stuart A Chief People & Workp.. Chief People & Workpl Officer Jan 31 Buy 3.17 2,254 7,145 622,785 02/09/22
Binder Steven B. Chief Financial Offi.. Chief Financial Officer Jan 31 Buy 3.17 711 2,254 534,178 02/02/22
Thomson David EVP Genl Counsel & S.. EVP Genl Counsel & Secretary Aug 27 Sell 4.64 4,100 19,024 567,391 08/27/21